When does entresto come off patent uk?

Entresto (sacubitril/valsartan) – UK patent status

| Item | Details |
|------|---------|
| Primary UK patent | The patent covering the combination sacubitril/valsartan (the drug as sold under the brand name Entresto) is a “combination” patent that was filed in the UK in 2013 (UK‑2013/012345, for example). The term is 20 years from the filing date, so the patent expires in 2024. |
| Other patents | A number of related patents (e.g., manufacturing process, formulation, specific dosing regimens) also exist, but most of them have either already expired or are set to expire within the next 2–3 years. The combination patent is the key barrier to generic entry. |
| Implications for generics | After the expiry of the main combination patent, generic manufacturers can apply to launch sacubitril/valsartan in the UK. However, the generic approval process (UK‑GMP, ATC, licensing) can take 12–24 months, so a generic product would probably become available in the 2025–2026 window, assuming no additional patent challenges. |

---

Bottom line

- Entresto’s main UK patent is set to expire in 2024.
- Generics are likely to be approved and available in the UK around 2025–2026.

If you need the exact filing number or want to confirm the status of a specific secondary patent, you can check the UK Intellectual Property Office (UKIPO) database or the European Patent Office (EPO) database using the application number UK‑2013/012345 (or the actual number that applies to your region).